Efforts at making the diagnosis of acute‐onset autoimmune hepatitis
Keiichi Fujiwara, Shin Yasui, Osamu Yokosuka – 30 March 2011
Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in patients undergoing transplantation for hepatocellular carcinoma
Gonzalo Sapisochin, Nicholas Fidelman, John P. Roberts, Francis Y. Yao – 24 March 2011 – Mixed hepatocellular cholangiocarcinoma (HCC‐CC) and intrahepatic cholangiocarcinoma (I‐CC) are increasingly being reported in patients with cirrhosis.
Nonalcoholic fatty liver disease activity score and Brunt's pathologic criteria for the diagnosis of nonalcoholic steatohepatitis: What do they mean and do they agree?
Stefano Ballestri, Amedeo Lonardo, Paola Loria – 24 March 2011
Reply:
Jin‐Kyu Park, Kyu‐Shik Jeong – 24 March 2011
Liver biopsy interpretation in liver cancer
Charles Balabaud – 24 March 2011
Reply:
René Adam, Eric Vibert, Jean‐Charles Duclos‐Vallee, Didier Samuel – 24 March 2011
What is the role of the receptor for advanced glycation end products–ligand axis in liver injury?
Giuseppina Basta, Teresa Navarra, Paolo De Simone, Serena Del Turco, Amalia Gastaldelli, Franco Filipponi – 24 March 2011 – Multiligand receptor for advanced glycation end products (RAGE) is expressed in a wide variety of tissues, including the liver. Interactions with its ligands lead to cellular activation and thus prolonged inflammation and apoptosis.
A simple trick for optimizing the three‐vein technique outflow anastomosis in piggyback liver transplantation
Umberto Baccarani, Vittorio Cherchi, Anna Rossetto, Dario Lorenzin, Gian Luigi Adani – 24 March 2011
No transfats
Brent A. Neuschwander‐Tetri – 24 March 2011
Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice
Chanunta Hongthanakorn, Watcharasak Chotiyaputta, Kelly Oberhelman, Robert J. Fontana, Jorge A. Marrero, Tracy Licari, Anna S. F. Lok – 24 March 2011 – Virological breakthrough (VBT) is the first manifestation of antiviral drug resistance during nucleos(t)ide analogue (NUC) treatment of chronic hepatitis B (CHB), but not all VBTs are due to drug resistance. This study sought to determine the incidence of VBT and genotypic resistance (GR) in patients with CHB who were receiving NUCs in clinical practice. Records of patients with CHB who were receiving NUCs were reviewed.